UCB unit to pay $22 million in US false claim settlement on Medicare reimbursement
This article was originally published in Scrip
Executive Summary
Schwarz Pharma, a unit of UCB, has agreed to pay $22 million to settle allegations that it failed to notify the Centers for Medicare and Medicaid Services that two of its unapproved products did not qualify for federal coverage, the US Justice Department said. The government had decided to join two whistleblower lawsuits.